A leading biopharmaceutical powerhouse, renowned for pioneering innovative drug development and biologics, is showing promising signs of market recovery. Recent financial moves include a strategic equity acquisition in its biologics division and an impressive 200% quarter-over-quarter profit growth, sparking investor interest as reflected in the company’s robust share price performance and market valuation. Share Price … Continue reading Is Biocon on the track to recovery?